Solventum Corp
About Solventum Corp
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V. site management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies; Dental Solutions, offering dental and orthodontic products such as brackets, restorative cements, and bonding agents; and Health Information Systems, providing software solutions including physician documentation, coding automation, speech recognition, and data visualization platforms. It operates in the United States, which earns the majority of revenue, and internationally.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $8.3B
- Net income
- $1.6B
- Total assets
- $14.3B
- Market cap
- $14.0B
- Gross margin
- 53.5%
- Operating margin
- 26.2%
- Net margin
- 18.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $8.3B
- Cost of revenue
- $3.9B
- Gross profit
- $4.5B
- Operating expenses
- $2.3B
- Operating income
- $2.2B
- Income tax
- $157.0M
- Net income
- $1.6B
- EPS (basic)
- $8.94
- EPS (diluted)
- $8.88
Balance sheet
- Total assets
- $14.3B
- Current assets
- $3.9B
- Total liabilities
- $9.2B
- Current liabilities
- $3.1B
- Shareholders’ equity
- $5.0B
Cash flow
- Operating cash flow
- $369.0M
- Investing cash flow
- $2.8B
- Financing cash flow
- -$3.1B
- Net cash flow
- $109.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $14.0B
- P/E ratio
- 8.9
- EPS (diluted)
- $8.88
- Shares outstanding
- 178.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 26, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $1.6B in FY2025.
- Revenue grew 1% from FY2024 to FY2025.
- Gross margin of 53.5%, net margin 18.7%.
- Trading 9% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 8.9.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Solventum Corp.
Write a review
News about Solventum Corp
News & sentiment via Polygon.io
